These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12439227)

  • 1. New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.
    Chida M; Ariyoshi N; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T
    Pharmacogenetics; 2002 Nov; 12(8):659-62. PubMed ID: 12439227
    [No Abstract]   [Full Text] [Related]  

  • 2. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM; Atchison BA; Somogyi AA; Drummer OH
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract]   [Full Text] [Related]  

  • 3. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.
    Sachse C; Brockmöller J; Hildebrand M; Müller K; Roots I
    Pharmacogenetics; 1998 Apr; 8(2):181-5. PubMed ID: 10022755
    [No Abstract]   [Full Text] [Related]  

  • 6. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
    Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L
    Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.
    Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T
    Pharmacogenetics; 1999 Jun; 9(3):287-93. PubMed ID: 10471060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
    Løvlie R; Daly AK; Molven A; Idle JR; Steen VM
    FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
    Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
    Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 polymorphism in systemic lupus erythematosus patients.
    Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
    Eur J Clin Pharmacol; 1999 Mar; 55(1):21-5. PubMed ID: 10206080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction.
    Roberts R; Joyce P; Kennedy MA
    Hum Mutat; 2000; 16(1):77-85. PubMed ID: 10874309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
    Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
    Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.